Endocrine & Metabolism Research Institute

Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Tuesday, November 7, 2023
FDA, Research, Hepatitis B virus, Principal investigator, University of Oxford, Heart rate, Three Months, Obesity, RNA, Diabetes, Fast Track, Weight loss, EST, Blood pressure, Fibrosis, CHB, Liver disease, Exercise, Endocrine & Metabolism Research Institute, NASH, Risk, Diet, Arrhythmia, HBV, NAFLD, Safety, Overweight, Vital signs, Medicine, Investment, Waist, Human, Non-alcoholic fatty liver disease, DNA, Clothing, Cryptocurrency, Dietary supplement, Pharmaceutical industry, Vaccine, Rare-earth element, Webcast, HBsAg

GAITHERSBURG, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended September 30, 2023, and provided a business update.

Key Points: 
  • Webcast to be held today, November 7, 2023, at 8:30 am EST
    GAITHERSBURG, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended September 30, 2023, and provided a business update.
  • Top-line results after 24 weeks of treatment are expected in the first quarter of 2025.
  • Financial Results for the Three Months Ended September 30, 2023
    Cash, cash equivalents and short-term investments totaled $140.8 million as of September 30, 2023.
  • General and administrative expenses were consistent period-over-period at $4.5 million for the three months ended September 30, 2023 and 2022.

Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, August 10, 2023
Blood pressure, Exercise, University of Oxford, DNA, Obesity, Dyslipidemia, Diet, NASH, Diabetes, Principal investigator, Weight loss, Endocrine & Metabolism Research Institute, CHB, Hepatitis B virus, RNA, Arrhythmia, EDT, Medicine, Fibrosis, Waist, Vital signs, Patient, Investment, IMPACT, Fatty liver disease, Overweight, NAFLD, Heart rate, Research, Three Months, HBV, Human, Safety, Hepatitis, Cryptocurrency, Dietary supplement, Pharmaceutical industry, Vaccine, HBsAg, Webcast

GAITHERSBURG, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended June 30, 2023, and provided a business update.

Key Points: 
  • Webcast to be held today, August 10, 2023, at 8:30 am EDT
    GAITHERSBURG, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended June 30, 2023, and provided a business update.
  • We are also eager to report our 48-week data from the MOMENTUM Phase 2 obesity trial next quarter.
  • Financial Results for the Three Months Ended June 30, 2023
    Cash, cash equivalents and short-term investments totaled $160.0 million as of June 30, 2023.
  • Interest income for the three months ended June 30, 2023 was $1.8 million as compared to $0.3 million in the same period in 2022.

City of Hope receives $32.3 million from the California Institute for Regenerative Medicine to advance innovative therapies for patients

Retrieved on: 
Wednesday, August 9, 2023
City of Hope, Diabetes, Bone marrow, California Institute for Regenerative Medicine, University of California, San Diego Performance-Based Skills Assessment, Patient, Division, CIRM, Canadian Aviation Regulations, Sickle cell disease, University, Gene, Endocrine & Metabolism Research Institute, Aplastic anemia, Research, Transplant, Immunology, Luca Zaia, Distinguishing, Safety, Cytomegalovirus, HLA, Cancer, Morgan, UCSD, Cell, Acute myeloid leukemia, CAR, CD33, Immune system, Food and Drug Administration, Mortality, LOS, B cell, Radiation, HIV, Clinical trial, Person, Irell & Manella Graduate School of Biological Sciences, Regenerative medicine, AML, City, Beckman Research Institute, Aaron, Haematopoietic system, Food, Vaccine, Pharmaceutical industry, Dentistry, Hope, Leukemia, Hematology

LOS ANGELES, Aug. 9, 2023 /PRNewswire/ -- Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, were awarded $32.3 million from the California Institute for Regenerative Medicine (CIRM) to support three novel Phase 1 clinical trials evaluating innovative cell and gene therapy treatments for patients with HIV, acute myeloid leukemia and severe aplastic anemia. 

Key Points: 
  • Beckman Research Institute of City of Hope was awarded two-thirds of the $50 million in this latest round of CIRM awards, the highest of any entity in the state.
  • City of Hope is a leader in gene therapies, including bone marrow and blood stem cells transplants.
  • "We are hopeful that this will provide another treatment option for patients with this devastating disease and thankful for CIRM's funding."
  • City of Hope has treated patients with sickle cell diseases using this novel therapy in a clinical trial also funded by CIRM.

City of Hope diabetes experts present new research on beta cells, insulin secretion and islet transplantation at annual American Diabetes Association (ADA) Conference

Retrieved on: 
Tuesday, June 27, 2023
Ruth B., Insulin resistance, City of Hope, Failure, Life, Drug discovery, Mitochondrion, Survival, Glucagon, Science, Metabolism, Patient, American Diabetes Association, ADA, AKT1, Conditional sentence, City of Hope National Medical Center, Endocrine & Metabolism Research Institute, Ageing, Epigenetics, Research, Overnutrition, Liver, DNA, Insulin, Cancer, Cell, Transplant, LOS, Therapy, Translation, Molecule, Arthur, Glucose, Clinical trial, Nutrient, Quality of life, Genomics, Inflammation, Proteomics, Metabolomics, Endocrinology, Gene, Medical device, Pharmaceutical industry, Phosphorus, Antibiotics, Dietary supplement, Dentistry, Hope, City, Diabetes

City of Hope diabetes scientists presented research at American Diabetes Association conference.

Key Points: 
  • City of Hope diabetes scientists presented research at American Diabetes Association conference.
  • Sangeeta Dhawan, Ph.D. , an associate professor in City of Hope's Department of Translational Research & Cellular Therapeutics , discussed epigenetic control of beta cell stress response and senescence.
  • Recent research by Dhawan and members of her lab outlined novel findings identifying the mechanisms by which cellular stress causes senescence.
  • Islet transplantation involves isolating insulin producing cells from a donated pancreas and infusing them into a patient with diabetes.

Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial

Retrieved on: 
Tuesday, March 21, 2023
Blood pressure, Exercise, Hyperglycemia, Obesity, Dyslipidemia, Diet, AE, NASH, Diabetes, Diarrhea, Week, Liver disease, Principal investigator, Aes, Weight loss, Cardiovascular disease, Constipation, Endocrine & Metabolism Research Institute, Risk, Medicine, Vomiting, Waist, Patient, Physician, LDL, Overweight, Weill Cornell Medicine, Nausea, Heart rate, Research, GI, Safety, Fasting, Female, Glycated hemoglobin, Human, Dietary supplement, Pharmaceutical industry

GAITHERSBURG, Md., March 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the “Company”), today announced topline results from a Week 24 interim analysis of 160 subjects in its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide along with the results of the 12-week Phase 1b safety trial of pemvidutide in subjects with obesity or overweight and type 2 diabetes.

Key Points: 
  • The trial was designed to enroll approximately 320 subjects with obesity or overweight with at least one co-morbidity and without diabetes.
  • Subjects were randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 48 weeks in conjunction with diet and exercise.
  • A pre-specified interim analysis was conducted after 160 subjects completed 24 weeks of treatment.
  • We look forward to completing our 48-week MOMENTUM obesity trial in the fourth quarter of 2023 and initiating a Phase 2 biopsy NASH trial in mid-2023.”